CS99 - I have heard DM say that apabetalone tells the body to produce new flat HDL particles that pick-up stuff on the artery walls a number of times in the past. Seem like that worked best in conjunction with Crestor in the post hock analysis of the Phase II trials but not with Lipitor.
If my memory hasn't failed me when torcetrapib blew up in 2008 it took US$28 billion off of the market cap of PFE. If you want an idea of what a safe, effective cardio drug is worth in the market, keep that number in mind. You may have to use an inflation factor to bring it up to date.